Figure 1.

Characteristics of DNMT3A^MT in our cohort of patients with myeloid neoplasms. (a) Illustration of position of DNMT3A^MT in chromosome 2 in our cohort of patients with myeloid neoplasia (left). Prevalence of DNMT3A^MT in different age groups in comparison to DNMT3A^WT (center). Maximum prevalence of DNMT3A^MT between age group 66–75 years. Distribution of different DNTMT3A^MT variants among different myeloid malignancies in the whole cohort (right). Canonical R882 variant is strongly associated with pAML than truncating or NCMS DNMT3A^MT (*P < 0.05). (b) ‘Tornado chart’ (left) demonstrating associated mutations in DNMT3A^MT and in wild-type patients with different myeloid neoplasia. Bar graph (right) shows significantly different other associated myeloid mutations in R882, NCMS and truncating DNMT3A^MT variants. There is a higher association of NPM1 in R882 variant, APC, IDH1 and SETBP1 in truncating variant and ASXL1, PRPF8 and RAD21 in NCMS DNMT3A^MT. (c) Illustrates clonal architecture in R882, truncating and NCMS variants of DNMT3A^MTmyeloid neoplasms.